Wire
Kenvue Increases Quarterly Dividend to $0.21 from $0.2075 a Share; Payable Aug. 26 to Holders of Record Aug. 12
Kenvue Increases Quarterly Dividend to $0.21 from $0.2075 a Share; Payable Aug. 26 to Holders of Record Aug. 12
$KVUE
$KVUE
13 stories mentioning KVUEUpdated 1d ago
Every FINWIRES story that references KVUE, newest first.
Wire
Kenvue's Tylenol With Naproxen Combination Tablet Gets FDA Approval for Pain Relief
Kenvue's (KVUE) Kenvue Brands unit received approval for its Tylenol with Naproxen combination tablet to provide up to 12 hours of pain relief in adults and children 12 years and older, the US Food and Drug Administration said Friday.The nonprescription combination product is indicated for temporary relief of minor aches and pains due to headache, backache, muscular aches, toothache, menstrual cramps, and minor arthritis pain, the FDA said.The agency said the approval was supported by data showing the effectiveness and safety of the combination drug.Kenvue shares were up about 1.1% in Friday trading.Price: $19.11, Change: $+0.21, Percent Change: +1.08%
$KVUE
Sectors
Sector Update: Healthcare Stocks Advance Late Afternoon
Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.5%.The iShares Biotechnology ETF (IBB) fell 1.4%.In corporate news, Conmed (CNMD) shares jumped 9% after Bloomberg Law reported that the company is exploring options including a potential sale amid takeover interest from private equity firms.A federal appeals court on Monday vacated a district court's earlier dismissal of plaintiff claims that they were not warned that prenatal ingestion of Kenvue's (KVUE) Tylenol and its generic equivalents could cause autism spectrum disorder and attention-deficit/hyperactivity disorder. Kenvue shares were down 1.5%.Humana (HUM) shares gained 4.1% after Wells Fargo upgraded the company's stock to overweight from equal-weight and increased the price target to $502 From $227.Hemab Therapeutics' (COAG) HMB-002 is particularly well suited for Type 1 von Willebrand disease patients despite encouraging early data from Incyte's (INCY) latarcibart, Wedbush Securities said in a note. Hemab shares rose 3.3%, and Incyte was down 1.5%.
$CNMD$COAG$HUM$INCY$KVUE
Sectors
Sector Update: Healthcare Stocks Higher Monday Afternoon
Healthcare stocks advanced Monday afternoon, with the NYSE Healthcare Index rising 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.4%.The iShares Biotechnology ETF (IBB) fell 1.6%.In corporate news, a federal appeals court on Monday vacated a district court's earlier dismissal of plaintiff claims that they were not warned that prenatal ingestion of Kenvue's (KVUE) Tylenol and its generic equivalents could cause autism spectrum disorder and attention-deficit/hyperactivity disorder. Kenvue shares were down 1.4%.Hemab Therapeutics' (COAG) HMB-002 is particularly well suited for Type 1 von Willebrand disease patients despite encouraging early data from Incyte's (INCY) latarcibart, Wedbush Securities said in a note. Hemab shares gained 6.5%, and Incyte was down 1.8%.Niagen Bioscience (NAGE) has received rare pediatric disease designation from the US Food and Drug Administration for NB4168 in treating ataxia telangiectasia, a multisystem disorder, the company said Monday. Its shares rose 1.6%.
$COAG$INCY$KVUE$NAGE
Wire
Update: Kenvue Must Face Claims Linking Tylenol to Autism, Appeals Court Says
(Updates with Kenvue's response to a request for comment in the last paragraph.)A federal appeals court on Monday vacated a district court's earlier dismissal of plaintiff claims that they were not warned that prenatal ingestion of Kenvue's (KVUE) Tylenol and its generic equivalents could cause autism spectrum disorder and attention-deficit/hyperactivity disorder.The two cases impacted by the appeals court ruling were remanded for further proceedings."The procedural ruling today does not change the fact that credible, independent science shows no proven link between taking acetaminophen and autism or attention deficit hyperactivity disorder," Kenvue said in a statement to. "Science matters, and we stand with the many public health and medical professionals who have reviewed the science on this topic and agree. We now have another opportunity to show that the plaintiffs' experts' opinions are unreliable and should not be allowed in this case. We stand behind the safety of our product and will continue to defend these cases."Price: $19.18, Change: $-0.31, Percent Change: -1.57%
$KVUE
Wire
Top Midday Stories: Trump Says US to Be Guardian of Hormuz Strait; Meta to Invest Over $50 Billion in Louisiana Data Center Expansion
All three major US stock indexes were down in late-morning trading Monday, as the US and Iran exchanged airstrikes over the weekend.President Donald Trump said Monday on Truth Social that the US will act as "THE GUARDIAN OF THE HORMUZ STRAIT" and will receive reimbursement for all incurred costs "at the rate of 20% on all cargo shipped." Trump said the strait is open and will remain so for all non-Iranian vessels.In company news, Meta Platforms (META) said Monday it plans to invest over $50 billion in its Richland Parish, Louisiana, infrastructure project to expand its computing capacity to 5 gigawatts. The tech giant will finance seven new natural gas-generating plants and three grid-scale batteries to completely cover its power requirements. Meta shares were down 1% around midday.Funds managed by Blackstone (BX) Credit & Finance, in partnership with Apollo Global Management (APO) and KKR-managed (KKR) insurance vehicles will invest $5.34 billion in Williams' (WMB) five Power Innovation projects in exchange for a 49% noncontrolling equity interest in the projects, Williams said Monday. Blackstone shares were down 0.8%, and Williams shares were down 0.1%. Apollo and KKR shares were down 0.8% and 0.3%, respectively.Taiwan Semiconductor Manufacturing (TSM) said Monday its net revenue for June totaled about 442.68 billion New Taiwan dollars ($13.79 billion), up 6.2% from the previous month and up 67.9% from a year earlier. Its shares were down 1.2%.First Hawaiian (FHB) said Monday it has signed a definitive agreement to acquire TriCo Bancshares (TCBK) in an all-stock deal. Under the deal terms, TriCo shareholders will receive 2.095 First Hawaiian shares for each TriCo share, valued at $63.12 per share based on First Hawaiian's July 10 closing price. First Hawaiian shares were down 4.6%, while TriCo shares were up 10.5%.Ferguson Enterprises (FERG) said Monday it has entered into a definitive agreement to acquire FWI Holdings, or FloWorks, in a deal with an enterprise value of about $1.6 billion. The deal is expected to close in Q3, subject to regulatory approvals and closing conditions. Ferguson shares were up 2.1%.Roughly a dozen states are set to file a lawsuit Monday in federal court in an effort to block Paramount Skydance's (PSKY) acquisition of Warner Bros. Discovery (WBD), Bloomberg reported, citing a person familiar with the matter. Paramount and Warner Bros. shares were up 2.7% and 0.5%, respectively.A federal appeals court on Monday vacated a district court's earlier dismissal of plaintiff claims that they were not warned that prenatal ingestion of Kenvue's (KVUE) Tylenol and its generic equivalents could cause autism spectrum disorder attention-deficit/hyperactivity disorder. Kenvue shares were down 1.6%.Price: $662.82, Change: $-6.39, Percent Change: -0.95%
$APO$BX$KKR$KVUE$META$PSKY$TSM$WBD$WMB
Wire
Kenvue Must Face Claims Linking Tylenol to Autism, Appeals Court Says
A federal appeals court on Monday vacated a district court's earlier dismissal of plaintiff claims that they were not warned that prenatal ingestion of Kenvue's (KVUE) Tylenol and its generic equivalents could cause autism spectrum disorder and attention-deficit/hyperactivity disorder.The two cases impacted by the appeals court ruling were remanded for further proceedings.Kenvue didn't immediately reply to a request for comment from.Price: $19.30, Change: $-0.18, Percent Change: -0.95%
$KVUE
Wire
Kenvue Must Face Claims Linking Tylenol to Autism, Appeals Court Says
Kenvue Must Face Claims Linking Tylenol to Autism, Appeals Court Says
$KVUE
Insider Trading
Kenvue Insider Sold Shares Worth $679,691, According to a Recent SEC Filing
Matthew Orlando, General Counsel, on May 08, 2026, sold 38,491 shares in Kenvue (KVUE) for $679,691.SEC Filing:https://www.sec.gov/Archives/edgar/data/1944048/000194404826000100/xslF345X05/wk-form4_1778617643.xml
$KVUE
Research
Research Alert: CFRA Keeps Hold View On Shares Of Kenvue Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We maintain our 12-month target price at $19, which is 16.5x our 2027 EPS view of $1.15, a discount to the trading multiple of 18.1x since going public in 2023. We think this multiple is justified given the litigation overhang and limited visibility into KVUE's standalone performance (the company is no longer providing forward-looking guidance and hosting an analyst call) due to the pending acquisition by Kimberly-Clark (KMB), expected to close during Q2 2026. We increase our 2026 EPS estimate to $1.15 from $1.10 following this morning's Q1 earnings release. We maintain our 2027 EPS estimate at $1.15. Kenvue delivered a solid first quarter that demonstrated continued operational momentum. Net sales increased to $3,909M (+4.5% Y/Y) with organic growth of 0.7%. The performance suggests management's operational initiatives are gaining traction as the company approaches the transaction close. The transaction received shareholder approval in January 2026, and regulatory approvals are progressing.
$KVUE
Research
Research Alert: CFRA Keeps Hold View On Shares Of Kenvue Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We maintain our 12-month target price at $19, which is 16.5x our 2027 EPS view of $1.15, a discount to the trading multiple of 18.1x since going public in 2023. We think this multiple is justified given the litigation overhang and limited visibility into KVUE's standalone performance (the company is no longer providing forward-looking guidance and hosting an analyst call) due to the pending acquisition by Kimberly-Clark (KMB), expected to close during 2H 2026. We increase our 2026 EPS estimate to $1.15 from $1.10 following this morning's Q1 earnings release. We maintain our 2027 EPS estimate at $1.15. Kenvue delivered a solid first quarter that demonstrated continued operational momentum. Net sales increased to $3,909M (+4.5% Y/Y) with organic growth of 0.7%. The performance suggests management's operational initiatives are gaining traction as the company approaches the transaction close. The transaction received shareholder approval in January 2026, and regulatory approvals are progressing.
$KVUE
Research
Research Alert: Kenvue Reports Solid Q1 Performance Amidst Pending Kimberly-clark Acquisition
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Kenvue (KVUE) delivered solid Q1 results with net sales of $3,909M (+4.5% Y/Y) and organic growth of 0.7%, marking the second consecutive quarter of growth. Diluted EPS surged to $0.25 vs. $0.17 (+47%) while adjusted EPS reached $0.32 vs $0.24 (+33%), due to significant margin expansion with gross margin improving 90bps to 58.9% and operating margin jumping 470bps to 19.6%. The strong performance demonstrates operational momentum ahead of the pending Kimberly-Clark acquisition, with supply chain optimization and cost management initiatives driving results. . Segment performance was mixed, with Skin Health & Beauty leading at +8.4% growth while Self Care faced headwinds from weak cold/flu seasons, posting an organic sales decline of 2.3%. Since management is no longer providing forward guidance and hosting an analyst call due to the transaction expected to close during 2H 2026, we have limited visibility into KVUE's performance expectations at this point.
$KVUE
Wire
Kimberly-Clark Shows Steady Performance Amid Volatile Macros, RBC Says
Kimberly-Clark (KMB) showed a steady Q1 performance amid volatile macros and Kenvue (KVUE) acquisition, RBC Capital Markets said in a note on Wednesday.The report said the company topped organic sales and earnings per share expectations in the quarter."Share performance in the US and internationally signals strong fundamentals and that ongoing M&A activity (Suzano JV and KVUE acquisition) is not impacting execution," the note said.Guidance was largely reiterated, and the firm pointed to potential inflation in H2 on rising oil prices, the note said, adding that new guidance will be issued if the Kenvue deal closes in H2."We continue to see more upside than downside to KMB," it said. RBC kept its outperform rating with a $162 price target.Price: $96.96, Change: $-1.48, Percent Change: -1.50%
$KMB$KVUE
